

## Tislelizumab

### for untreated HER2-negative, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

Technology Guidance from the MOH Drug Advisory Committee

#### Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

- ✓ Tislelizumab 100 mg/10 mL concentrate for solution for infusion, in combination with fluoropyrimidine and platinum-based chemotherapy, for untreated, unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma with a PD-L1 expression  $\geq 1\%$ .

The decision was based on the acceptable clinical effectiveness and potential cost savings to the healthcare system.

#### Funding status

Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2026.

***Clinical indication, subsidy class and MediShield Life claims eligibility for tislelizumab are provided in the Annex.***

## ANNEX

### Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class (implementation date)	Eligible for MediShield Life claims (implementation date)
Tislelizumab 100 mg/10 mL concentrate for solution for infusion	Tislelizumab in combination with fluoropyrimidine and platinum-based chemotherapy for untreated, unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma with a PD-L1 expression $\geq 1\%$ .	MAF (1 Sep 2026)	Yes <sup>1</sup> (1 Sep 2026)

Abbreviation: MAF, Medication Assistance Fund.

<sup>1</sup> Please refer to MOH's website for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

#### About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore  
 Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.